Fast Track status enables expedited regulatory review timelines and supportsthe development of recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases.
EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints